Skip to main
OSTX

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies Inc. has achieved significant regulatory milestones that enhance its prospects for the approval of its drug OST-HER2 in the treatment of metastatic osteosarcoma, notably through a successful Type C meeting with the FDA and alignment with the UK MHRA. The company’s strategic regulatory positioning, including eligibility for Union-wide marketing authorization in Europe, supports a streamlining of its filing processes and potentially accelerates market entry. Importantly, the innovative mechanism of OST-HER2, targeting critical immune pathways, aligns with emerging oncological research that indicates improved outcomes for osteosarcoma treatment, signaling a promising future for the company.

Bears say

OS Therapies Inc faces significant challenges due to the inherent characteristics of osteosarcoma, which does not effectively respond to receptor-level HER2 inhibition and is characterized as immunologically “cold” and genetically unstable. This complicates the development of targeted therapies, limiting the potential for successful treatment options and market competitiveness. Furthermore, the poor responsiveness of osteosarcoma to antibody biology raises concerns about the viability of the company's product pipeline and its ability to deliver revenue-generating therapies in the near future.

OSTX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 3 analysts, OSTX has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.